Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

BYSIBullishCorporate Developmentsnews

High materiality7/10

BeyondSpring's ASCO data reinforce Plinabulin path; leadership targets DUBLIN-4

Aug 14, 2026, 5:18 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Positive ASCO/AACR data and a cleared path to DUBLIN-4 can unlock upside, but near-term liquidity risk and need for financing lend moderate dilution risk.

AI summary

What happened, with direct paths to the underlying reporting

BeyondSpring's Q2 2026 results highlight ASCO data showing 58% two-year OS in post-ICI NSCLC with Plinabulin-based therapy, reinforcing DUBLIN-4 as the lead Phase 3. AACR findings support ADC combinations. A July 1 leadership transition aligns management with DUBLIN-4 execution and financing efforts, signaling near-term catalysts but keeping liquidity risk in focus.

ASCO 2026: Plinabulin combo shows 58% two-year OS in post-ICI NSCLC.
AACR 2026: Plinabulin improves ADC efficacy and tolerability in preclinical data.
Leadership transition effective July 1, 2026 to drive DUBLIN-4 execution.
Q2 2026: cash $6.5M; net loss $1.8M; year-to-date net loss $4.1M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.